Therapy-related myeloid neoplasms following treatment for multiple myeloma—a single center analysis

[1]  M. Boccadoro,et al.  Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial , 2020 .

[2]  T. Keegan,et al.  Second primary malignancies in multiple myeloma: A review. , 2020, Blood reviews.

[3]  J. Esteve,et al.  Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS , 2020, Leukemia.

[4]  F. Prósper,et al.  Biological and clinical significance of dysplastic hematopoiesis in patients with newly-diagnosed multiple myeloma. , 2020, Blood.

[5]  Andre H Crepaldi,et al.  Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial , 2019, The Lancet.

[6]  F. Ortuño,et al.  Increasing therapy‐related myeloid neoplasms in multiple myeloma , 2018, European journal of clinical investigation.

[7]  W. Wiktor-Jedrzejczak,et al.  Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents. , 2018, Biology of Blood and Marrow Transplantation.

[8]  H. Einsele,et al.  Second primary malignancies in multiple myeloma: an overview and IMWG consensus. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[10]  F. Prósper,et al.  The Presence of MDS-like Phenotypic Abnormalities (MDS-PA) Identifies Newly Diagnosed Multiple Myeloma (MM) Patients with MDS/AML-Related Somatic Mutations and Inferior Survival , 2016 .

[11]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[12]  A. Krishnan,et al.  New cancers after autotransplantations for multiple myeloma. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  V. Baladandayuthapani,et al.  Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia. , 2015, Clinical lymphoma, myeloma & leukemia.

[14]  S. Ely,et al.  Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens. , 2012, American journal of clinical pathology.

[15]  S. Chakraborty,et al.  Increased incidence of a second lymphoproliferative malignancy in patients with multiple myeloma--a SEER based study. , 2012, Anticancer research.

[16]  A. Órfão,et al.  Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide? , 2012, Haematologica.

[17]  A. Trumpp,et al.  Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells. , 2012, Blood.

[18]  M. Beksac,et al.  Continuous lenalidomide treatment for newly diagnosed multiple myeloma. , 2012, The New England journal of medicine.

[19]  B. Pégourié,et al.  Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.

[20]  R. Schlenk,et al.  Therapy-related myeloid neoplasms following treatment with radioiodine , 2012, Haematologica.

[21]  U. Germing,et al.  Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry. , 2011, Leukemia research.

[22]  R. Pfeiffer,et al.  Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). , 2011, Blood.

[23]  H. Deeg,et al.  Treatment-related myelodysplastic syndrome: molecular characteristics and therapy , 2011, Current opinion in hematology.

[24]  K. Döhner,et al.  The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. , 2011, Blood.

[25]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[26]  R. Larson.  Therapy-related myeloid neoplasms , 2009, Haematologica.

[27]  R. Larson,et al.  Therapy-related myeloid leukemia. , 2008, Seminars in oncology.

[28]  Thomas H Müller,et al.  New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.

[29]  A. Al-Katib,et al.  Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes , 2007, American journal of hematology.

[30]  M. Voso,et al.  Therapy-related leukemia and myelodysplasia: susceptibility and incidence , 2007, Haematologica.

[31]  U. Germing,et al.  Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7. , 2005, Haematologica.

[32]  P. Macpherson,et al.  Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. , 2004, Blood.

[33]  W. Hiddemann,et al.  Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML , 2004, Leukemia.

[34]  Sonali M. Smith,et al.  Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. , 2003, Blood.

[35]  B. Barlogie,et al.  Cytogenetic findings in 200 patients with multiple myeloma. , 1995, Cancer genetics and cytogenetics.

[36]  H. Wilson,et al.  Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. , 1969, JAMA.